Cialis Alcohol Interaction Among Key Factors Preventing First-Cycle Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly/Icos’ handling of Cialis’ interaction with alcohol appears to have been a sore point with FDA, review documents for the erectile dysfunction therapy indicate.
You may also be interested in...
Cialis Prolonged Activity Widens Nitrate Concern; Risk Management Requested
Cialis’ distinguishing feature – its longer window for efficacy than competing erectile dysfunction agents – also triggered concerns about a longer window for safety problems with the Lilly/Icos drug, FDA review documents indicate.
Lilly/Icos Cialis Development Strategy: FDA Delays Phase IIIs – Go Overseas
Lilly/Icos’ Cialis NDA was based on Phase III studies conducted outside the U.S. after FDA advised the firm at an end-of-Phase II meeting to delay pivotal studies until potential testicular toxicity could be investigated, FDA review documents show.
Lilly/Icos Cialis Development Strategy: FDA Delays Phase IIIs – Go Overseas
Lilly/Icos’ Cialis NDA was based on Phase III studies conducted outside the U.S. after FDA advised the firm at an end-of-Phase II meeting to delay pivotal studies until potential testicular toxicity could be investigated, FDA review documents show.